Fulzerasib with immunotherapy and chemo before surgery for KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted pill (Fulzerasib) and immunotherapy (Sintilimab) plus standard chemotherapy before surgery, for people with early-stage non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that has not spread beyond the chest (stage IB to IIIA) and is considered removable by surgery.
- Your tumor must have a KRAS G12C mutation, confirmed by a test, and must not have EGFR or ALK mutations.
- You must be at least 18 years old and in good overall health, with a performance status of 0 or 1 (able to carry out daily activities).
- You must have at least one measurable tumor on scans, and adequate organ function (kidney, liver, bone marrow).
- You must not have had prior cancer treatment for this disease, active infections, certain heart or lung conditions, or a history of other cancers within the last 5 years (except for cured skin or in-situ cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It is for people whose cancer has not responded to standard treatments.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
This study tests a new combination of drugs before surgery for people with a certain type of lung cancer (KRAS G12C). The goal is to see if these drugs can shrink the tumor and improve chances of successful surgery.
This trial tests a combination of an immunotherapy drug (Rilpufan α) with chemotherapy given before surgery for early-stage (stage II-III) non-small cell lung cancer. The goal is to shrink the tumor to make surgery more effective and potentially improve long-term outcomes.
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
Hear when a new KRAS G12C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.